Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ascorbate + azacitidine + venetoclax
- Development stage
- Unknown
- Lead developer
- University of Iowa
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This investigational combination therapy, consisting of high-dose intravenous ascorbate (vitamin C), azacitidine, and venetoclax, is being evaluated for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. The regimen is the subject of a Phase I clinical trial led by Dr. Kittika Poonsombudlert at the University of Iowa. The biological rationale involves ascorbate's role as a cofactor for TET2 and other 2-oxoglutarate-dependent dioxygenases, which are often mutated or downregulated in AML; by restoring TET2 function, ascorbate may enhance the epigenetic effects of the hypomethylating agent azacitidine. Additionally, pharmacological doses of ascorbate generate reactive oxygen species that selectively target leukemic cells. Venetoclax complements this by inhibiting BCL-2, an anti-apoptotic protein frequently overexpressed in AML, thereby lowering the threshold for programmed cell death.
- Other names
- High-dose ascorbate in combination with azacitidine and venetoclaxHDA + Aza/VenHigh-dose ascorbate + azacitidine + venetoclax
02
Targets
DNMT (DNA methyltransferase)TET2 (Methylcytosine dioxygenase TET2)
Beyond the preview
Go deeper on ascorbate + azacitidine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ascorbate + azacitidine + venetoclax.